DENTSPLY International Inc. has announced that it has entered into a joint
development agreement with Two Cells Co. Ltd. (based in Hiroshima, Japan) regarding regeneration therapy utilizing neurotrophin (BDNF) for periodontal disease.
As part of this agreement, Two Cells and Professor Hidemi Kurihara (Department of Periodontal Medicine, Division of Frontier Medical Science, Hiroshima University Graduate School of Biomedical Sciences) have granted DENTSPLY a worldwide license for this exciting technology.
For its part, DENTSPLY will provide development funding to Two Cells. DENTSPLY, through its Office of Advanced Technology, continues to pursue outside technologies such as this, that may provide opportunities for future, innovative solutions to dentistry.
Gary Kunkle, DENTSPLY's Chairman and Chief Executive Officer, stated, "Our Office of Advanced Technology continues to identify exciting new technologies which will be used to advance the future of dentistry. This license agreement is based on an international patent application titled 'Remedy and Therapeutic Method for Periodontal Diseases and Pulpal Diseases' submitted by Professor Hidemi Kurihara of Hiroshima University and the University's venture company, Two Cells Co. Ltd. To date, this applied research into periodontal therapy using BDNF is unprecedented worldwide and its potential application in periodontal regeneration therapy would provide a significant improvement in the treatment of this disease."
